Novartis's Zolgensma Finds Commercial Legs In A First For Gene Therapy

 
• By Jessica Merrill

Zolgensma generated $160m in the third quarter, a strong launch for the gene therapy's first full quarter on the market.

Paper plane as spaceship flying above clouds to another planet, mars. Business background for success, launch, startup, technology innovation, exploration, mission. Eps10 vector illustration. - Vector
Novartis' Zolgensma got off to a strong start

More from Earnings

More from Business